网站综合信息 avastin.com
- 标题:
- Avastin® (bevacizumab) Efficacy, Safet
- 关键字:
- 描述:
- Learn about Avastin® (bevacizumab) for FDA-approved indications. See full safety & Boxed War
- 域名信息
- 域名年龄:23年12个月3天 注册日期:2001年03月16日 到期时间:2017年03月16日
邮箱:domainabuse 电话:+1.8887802723
注册商:CSC CORPORATE DOMAINS, INC.
- 服务器空间
- IP:52.52.174.250
地址:美国 特拉华州dupont公司
- 备案信息
- 备案号:
域名流量Alexa排名
域名注册Whois信息
avastin.com
域名年龄: 23年12个月3天注册时间: 2001-03-16
到期时间: 2017-03-16
注 册 商: CSC CORPORATE DOMAINS, INC.
注册邮箱: domainabuse
联系电话: +1.8887802723
获取时间: 2016年09月26日 03:46:52
Domain Name: AVASTIN.COM
Registrar: CSC CORPORATE DOMAINS, INC.
Sponsoring Registrar IANA ID: 299
Whois Server: whois.corporatedomains.com
Referral URL: http://www.cscglobal.com/global/web/csc/digital-brand-services.html
Name Server: DNADNS2E.GENE.COM
Name Server: DNADNS3E.GENE.COM
Name Server: DNADNS4E.GENE.COM
Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Updated Date: 2016-03-11
Creation Date: 2001-03-16
Expiration Date: 2017-03-16
>>> Last update of whois database: Sun, 2016-Sep-25 19:49:53 GMT <<<
For more information on Whois status codes, please visit https://icann.org/epp
Domain Name: avastin.com
Domain ID: 67886488_DOMAIN_COM-VRSN
WHOIS Server: whois.corporatedomains.com
Referral URL: www.cscprotectsbrands.com
Updated Date: 2016-03-11T06:48:04Z
Creation Date: 2001-03-16T02:11:53Z
Registry Expiry Date: 2017-03-16T01:11:53Z
Sponsoring Registrar: CSC CORPORATE DOMAINS, INC.
Sponsoring Registrar IANA ID: 299
Registrar Abuse Contact Email: domainabuse
Registrar Abuse Contact Phone: +1.8887802723
Domain Status: clientTransferProhibited http://www.icann.org/epp#clientTransferProhibited
Registry Registrant ID:
Registrant Name: Genentech, Inc Genentech, Inc
Registrant Organization: Genentech, Inc
Registrant Street: 1 DNA Way
Registrant City: South San Francisco
Registrant State/Province: CA
Registrant Postal Code: 94080-4918
Registrant Country: US
Registrant Phone: +1.
Registrant Phone Ext:
Registrant Fax:
Registrant Fax Ext:
Registrant Email: domain-management-d
Registry Admin ID:
Admin Name: Genentech, Inc Genentech, Inc
Admin Organization: Genentech, Inc
Admin Street: 1 DNA Way
Admin City: South San Francisco
Admin State/Province: CA
Admin Postal Code: 94080-4918
Admin Country: US
Admin Phone: +1.
Admin Phone Ext:
Admin Fax:
Admin Fax Ext:
Admin Email: domain-management-d
Registry Tech ID:
Tech Name: Genentech, Inc Genentech, Inc
Tech Organization: Genentech, Inc
Tech Street: 1 DNA Way
Tech City: South San Francisco
Tech State/Province: CA
Tech Postal Code: 94080-4918
Tech Country: US
Tech Phone: +1.
Tech Phone Ext:
Tech Fax:
Tech Fax Ext:
Tech Email: domain-management-d
Name Server: dnadns4e.gene.com
Name Server: dnadns2e.gene.com
Name Server: dnadns3e.gene.com
DNSSEC: unsigned
URL of the ICANN WHOIS Data Problem Reporting System: http://wdprs.internic.net/
>>> Last update of WHOIS database: 2016-03-11T06:48:04Z <<<
For more information on Whois status codes, please visit https://icann.org/epp
Corporation Service Company(c) (CSC) The Trusted Partner of More than 50% of the 100 Best Global Brands.
Contact us to learn more about our enterprise solutions for Global Domain Name Registration and Management, Trademark Research and Watching, Brand, Logo and Auction Monitoring, as well SSL Certificate Services and DNS Hosting.
NOTICE: You are not authorized to access or query our WHOIS database through the use of high-volume, automated, electronic processes or for the purpose or purposes of using the data in any manner that violates these terms of use. The Data in the CSC WHOIS database is provided by CSC for information purposes only, and to assist persons in obtaining information about or related to a domain name registration record. CSC does not guarantee its accuracy. By submitting a WHOIS query, you agree to abide by the following
Register your domain name at http://www.cscglobal.com
网站头文件(HTTP Header)
HTTP/1.1 301 永久重定向 访问时间:2019年07月02日 05:18:02 目标网址:https://www.avastin.com/ 文件大小:232 Keep-Alive: timeout=5, max=100 连接:Keep-Alive 类型:text/html; charset=iso-8859-1 HTTP/1.1 200 OK 接受单位:字节 Content-Encoding: gzip 类型:text/html; charset=UTF-8 访问时间:2019年07月02日 05:18:02 动作:Accept-Encoding 文件大小:22978 连接:keep-alive 网站编码:UTF-8
同IP网站(同服务器)
其他后缀域名
网站首页快照(纯文字版)
抓取时间:2019年07月02日 05:18:04
网址:http://avastin.com/
标题:Avastin® (bevacizumab) Efficacy, Safety, Dosing & Prescr
关键字:
描述:Learn about Avastin® (bevacizumab) for FDA-approved indications. See full safety & Boxed Warnings for more information.
主体:
网址:http://avastin.com/
标题:Avastin® (bevacizumab) Efficacy, Safety, Dosing & Prescr
关键字:
描述:Learn about Avastin® (bevacizumab) for FDA-approved indications. See full safety & Boxed Warnings for more information.
主体:
For US Healthcare ProfessionalsFor Patients and CaregiversDosingContact a RepPrescribing InformationSafetySearchMenuCloseFor US Healthcare ProfessionalsFor Patients and CaregiversSelect IndicationColorectal Cancer (mCRC)Lung Cancer (nsNSCLC)Kidney Cancer (mRCC)Cervical Cancer (CC)Ovarian Cancer (OC)Recurrent Glioblastoma (GBM)Colorectal Cancer (mCRC)EfficacySafetyProposed MOADosingClinical and Patient ResourcesFinancialLung Cancer (nsNSCLC)EfficacySafetyProposed MOADosingClinical and Patient ResourcesFinancialKidney Cancer (mRCC)EfficacySafetyProposed MOADosingClinical and Patient ResourcesFinancialCervical Cancer (CC)EfficacySafetyProposed MOADosingClinical and Patient ResourcesFinancialOvarian Cancer (OC)EfficacySafetyProposed MOADosingClinical and Patient ResourcesFinancialRecurrent Glioblastoma (GBM)EfficacySafetyProposed MOADosingClinical and Patient ResourcesFinancialDosingContact a RepSafetyPrescribing InformationConfidence Built on EvidenceIn a changing treatment landscape, choose AvastinPlease select an indicationColorectal cancer (MCRC)EfficacySafetyDosingLung cancer (NSCLC)EfficacySafetyDosingKidney cancer (mRCC)EfficacySafetyDosingCervical cancer (CC)EfficacySafetyDosingOvarian cancer (OC)EfficacySafetyDosingGlioblastoma (GBM)EfficacySafetyDosing>2.2 million patientsLearn more about the extensive real-world experience with Avastin11 pivotal trialsSee Avastin approvals across endpoints and indicationsAccess and choiceFind out more about Genentech’s commitment to support patient accessand physician choiceAcross indications, Avastin has been usedto treat more than 2.2 million patients worldwide [3]PBRER=Periodic Benefit-Risk Evaluation Report.Patients treated is based on the PBRER report ofpatient exposure, which was calculated based on the global totalmilligram volume sales divided by the average dose per patient peryear, based on US approved indications. Average dose was based onthe monthly dose multiplied by treatment duration (in months).Assumption of patient exposures from the PBRER report may notnecessarily correspond to a unique patient. [3]Drug utilization assumptions were considered inorder to calculate the number of patients exposed to Avastin byindication worldwide, including US and Japan. Excluding Japan, theaverage body weight used worldwide was between 65-75 kg. Averagedose was based on the approved dose of each indication. Note: somedose interruptions may have been accounted for per cliniciandiscretion. In Japan, per sales assumption data, total dose was fromthe specific year of approval for each given indication.Ovarian cancer data are based on recurrent OConly; Avastin is also indicated in stage III or IV OC after primarysurgery, for which exposure data are not yet available. [3]Avastin is extensively studied: Avastin FDAapprovals based on 11 pivotal trials across 6 tumor types[1]FDA approvals based on multiple endpoints[1,8]1, 8For additional trial information, please select efficacy from theindication dropdown men
最近查询网站